Intravenous administration of the anti–vascular endothelial growth factor treatment bevacizumab at high doses can result in serious, systemic adverse events (AEs). Additionally, tumors can become resistant to therapy and adopt a more invasive growth pattern. Thus, delivering bevacizumab for the treatment of cancer at a lower dose in a manner that avoids systemic AEs is necessary.
Intravenous administration of the anti—vascular endothelial growth factor treatment bevacizumab at high doses can result in serious, systemic adverse events (AEs). Additionally, tumors can become resistant to therapy and adopt a more invasive growth pattern. Thus, delivering bevacizumab for the treatment of cancer at a lower dose in a manner that avoids systemic AEs is necessary.
A recent study, published in OncoTargets and Therapy, sought to evaluate the therapeutic effect of intratumoral low-dose bevacizumab versus high-dose treatment in glioma-bearing animals, and found that administering bevacizumab by intratumoral injection might be an effective protocol for treating gliomas by regulating the expression of inflammation and invasion-related factors and inhibiting cancer stem cells.
In mice implanted with glioma cells, researchers found that bevacizumab delivered by intratumoral injection or systemic (intravenous) administration was effective, but intratumoral injection was more efficient; the bioluminescence imaging signal used to assess tumor growth in mice treated intratumorally was less intense than it was in those treated with intravenous therapy.
Injected bevacizumab was also associated with increased survival; mice that received intratumoral injections had a median survival of 40 days versus 27 days in the intravenous therapy group.
The density of tumor blood vessels was also reduced in mice who received injections, as were invasive factors of tumors and cancer stem cells, versus mice who received systemic therapy. However, inflammatory factors of tumors increased in the injection group; cold-inducible RNA-binding protein, which mediates brain injury, was significantly increased in the injected group versus the systemic therapy group.
The authors concluded that localized delivery of bevacizumab was more effective in reducing tumor size and cell infiltration versus intravenous delivery, and could be considered an alternative to intravenous therapy. While more research will be necessary, the identification of this possibility serves as a first step, write the authors, to a novel delivery method that could overcome the AEs associated with systemic therapy.
Reference
Liu YX, L WJ, Zhang HR, Zhang ZW. Delivery of bevacizumab by intracranial injection: assessment in glioma model. Onco Targets Ther. 2018;11:2673-2683. doi: 10.2147/OTT.S159913.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.